Table 2 Stratified analyses of the MPO-463G > A polymorphism on cancer risk by cancer type
From: Association between MPO-463G > A polymorphism and cancer risk: evidence from 60 case-control studies
Study groups | A vs. G | AA vs. GG | AA vs. AG + GG | AA + AG vs. GG | ||||
|---|---|---|---|---|---|---|---|---|
OR (95%CI) | I 2 | OR (95%CI) | I 2 | OR (95%CI) | I 2 | OR (95%CI) | I 2 | |
Total | 0.90(0.84–0.95) | 0.571 | 0.84(0.76–0.94) | 0.417 | 0.87(0.78–0.97) | 0.366 | 0.89(0.83–0.95) | 0.520 |
Lung | 0.92(0.83–1.01) | 0.525 | 0.93(0.78–1.10) | 0.481 | 0.95(0.80–1.12) | 0.488 | 0.93(0.87–0.99) | 0.420 |
Breast | 0.98(0.83–1.16) | 0.545 | 0.99(0.75–1.30) | 0.441 | 1.00(0.76–1.32) | 0.342 | 0.96(0.85–1.08) | 0.418 |
Digestive | 0.71(0.57–0.87) | 0.694 | 0.63(0.37–1.05) | 0.529 | 0.77(0.57–1.02) | 0.415 | 0.67(0.53–0.84) | 0.619 |
Dig tract | 0.75(0.59–0.95) | 0.668 | 0.74(0.39–1.43) | 0.523 | 0.92(0.65–1.29) | 0.449 | 0.72(0.56–0.92) | 0.577 |
Dig gland | 0.63(0.40–0.98) | 0.700 | 0.41(0.23–0.72) | 0.355 | 0.51(0.29–0.89) | 0.000 | 0.58(0.35–0.96) | 0.649 |
Blood | 1.12(0.96–1.25) | 0.431 | 0.96(0.63–1.58) | 0.501 | 1.03(0.85–1.40) | 0.623 | 1.03(0.85–1.40) | 0.623 |